Drugs / Bacillus Calmette-Guerin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT01729663 | Apr 2009 → Dec 2018 | cutaneous melanoma | Laboratorio Pablo Cassará S.R.L. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacillus Calmette-Guerin | “The irradiated, allogeneic, cellular CSF-470 vaccine plus Bacillus Calmette-Guerin (BCG) and recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) is...” PMID 28620382 ↗ May 2017 |
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01729663 ↗ |
| Route | Other | “1.6 × 107 irradiated CSF-470 cells plus 106 colony-forming units BCG plus 100 µg rhGM-CSF were administered intradermally” PMID 28620382 ↗ May 2017 |